Wolfe Research has initiated coverage on Arcellx Inc (ACLX) with a Peer Perform rating, effective November 17, 2025. This marks the firm's first assessment of the company's investment potential.
Arcellx, headquartered in Redwood City, California, is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and other incurable diseases. The company employs 163 full-time staff and went public on February 4, 2022. Its lead program, anitocabtagene autoleucel, targets BCMA and is currently under evaluation in pivotal Phase II and Phase III trials for relapsed or refractory multiple myeloma.
As of November 18, 2025, Arcellx has a market capitalization of $5.2 billion and reported a trailing twelve months earnings per share (EPS) of -3.92. The company is scheduled to announce its next earnings results on March 16, 2026, with an estimated EPS of -1.05 and revenue of $16.1 million.
Analyst ratings reflect professional opinions based on research and financial models. They can provide useful perspectives but must be considered alongside company fundamentals, competitive positioning, and industry trends. The consensus rating for Arcellx remains a Buy, with 9 Strong Buy, 14 Buy, and 2 Hold ratings from analysts as of November 1, 2025.